Biopharma

Clinical-stage biopharma Surface Oncology, Inc. (NASDAQ: SURF) has developed a prosperous pipeline that targets the tumor micro-environment and leverages the innate and adaptive immune system, according to Baird Equity Research.  The Analyst Analyst Michael Ulz initiated coverage of...

M&A activity has begun in the New Year, with the pharma sector leading from the front. Earlier this week, the Wall Street Journal reported Celgene Corporation (NASDAQ: CELG) is pursuing Juno Therapeutics Inc (NASDAQ: JUNO). The report triggered a massive 52-percent upward move in shares of...

Axovant Sciences Ltd (NASDAQ: AXON)'s announcement this week that its lead drug candidate intepirdine failed in a late-stage trial comes after the stock lost 90 percent of its value over the past three months following a negative announcement on an Alzheimer's trial.  The Analyst...

Clinical-stage biopharma company Epizyme Inc (NASDAQ: EPZM)'s tazemetostat has shown effectiveness in treating blood cancers and solid tumors with minimal toxicities in early- and mid-stage trials, according to Morgan Stanley.  Tazemetostat is an EZH2 inhibitor that moderates gene...

The curtains have come down on one of the most-watched annual biotech conferences. The 59th annual meeting of the American Society of Hematology was held Dec. 9-12 in Atlanta.  This year's meeting was all about competition in the CART-T space. Immunotherapy — the fifth pillar of...

The American Society of Hematology's 59th annual meeting continues through Tuesday in Atlanta. Although stocks reacted to the presentation of abstracts in early November, the full presentation elicited incremental reaction, with the direction and magnitude of the moves dependent on the market...

Joshua Schimmer of Piper Jaffray commented in a note that he is "eager to hit the reset button" within the biopharma sector. Schimmer presented a list of potential outcomes and events in 2016 which represent contrarian views or ones that investors "aren't even...

Benzinga recently had the chance to talk with Jason Napodano, biopharma analyst and consultant, and owner of BioNap Consulting. Below is a look at some highlights from the expert. Macro Conditions And The Biotech Industry When asked about the current state of macro conditions for the biotech...